Good noon, everyone, and thank you for joining us today. I'm Geoff Raskin from IR. I'm pleased to have with us Laurent Nielly, our new CEO, and Geert Peeters, our CFO, to present the 2025 results. Before that, let me remind you of the safe harbor regarding forward-looking statements. I will not read it out loud, but I will assume you will have duly noted it. With that cleared up, Laurent, over to you. Thanks, Geoff, and before I dive into the results, allow me to say some words about me. First of all, let me share my appreciation for the board and for our former CEO, Gustavo Calvo Paz, for the trust and the support in this transition. I'm honored to take over and realize the challenges ahead, to both rebuild trust fast and to continue to work to unlock the intrinsic value of Ontex. I joined Ontex eight years ago to help turn around the just acquired business in Brazil, then moved to Europe with a mission to bring strategic discipline, drive the business back to growth, and to rebuild profitability after the inflationary shock in 2022. I have a deep understanding of our company, and I share the passion for our purpose, mission, and people. We have strong assets, potential, and I take on the assignment with high energy, but obviously also at a time of big disappointment after a challenging 2025. As you know, the year did not evolve as we had anticipated at the start of 2025, and we had to revise our outlook twice. The final results should be of no surprise to any of you, being in line with the outlook we communicated early December. Revenue was 5% lower, like for like, in a challenging market, and the Adjusted EBITDA came down by 2 percentage points, mainly due to the impact of lower volume. The 10% margin level is still demonstrating resilience of the business in a difficult year. We did better than we anticipated free cash flow, ending with -EUR 25 million. Net Debt benefited from the divestment proceeds with lower Adjusted EBITDA. Our leverage rose to 3.3 x. Let me expand a bit on the main elements that drove our results in the year on the next slide. Clearly, our volumes, which are the backbone of our business, did not meet our ambition with three key factors. We faced a softer demand in 2025, especially in baby care. We could not pivot on some of the growing segment as fast as we wanted in the midst of our transformation in Europe. That limited temporarily our flexibility, and this was amplified by some disruption in supply that we had discussed in previous quarters. And in North America, we experienced much more repeat decline in our contract manufacturing sales. Against this backdrop, we continued to preserve our competitive position, signing and starting delivery of new contracts, thereby maintaining our positive contract gain and loss balance for the year. We also continue to innovate in all three categories and are recognized on our sustainability performance, as illustrated recently with an A score from CDP. Most importantly, we reached some key milestones in our transformation journey. We completed the divestment of our emerging business. Our Belgium footprint work is progressing well, and in North America, we added production line in our North Carolina factory. Before I pass over to Geert on the financial analysis of the year, I'll quickly touch base on the fourth quarter performance. Our revenue came down by 7.6% like-for-like in Q4, versus a strong quarter last year. This is 2% lower than our third quarter of 2025, with demand softening further, especially in baby care, both in Europe and North America. You can see in the chart that the decrease and the volatility of revenue in the last 8 quarters is mostly linked to our baby care business, whereas adult has continuously grown, and in the last quarter represent 47% of our revenues. The lower volume in Q4 impacted the profitability, especially as we had anticipated growth and the Adjusted EBITDA margin, therefore, dropped three percentage points versus last year to 9%, which is 2.4 points decline quarter-on-quarter. While Q4 was again below our expectation, it is important for me to stress the many progress made on our transformation journey, which are strengthening the company and which will bear fruits in the months and years to come. Yet it is equally clear that more is needed to improve back our trajectory. With this, I pass over to Geert for a more detailed analysis on our full year results. Thanks a lot, Laurent, and hello, everyone. In the financial review, I will focus on the full year results and start, of course, with the revenue. On this slide, you will find the full year revenue bridge showing the 5% revenue decrease, which was almost entirely due to the volume decline by EUR 93 million. As Laurent already explained, this was caused mainly by the lower demand for retailer brands in baby care a nd specifically in North America, the decline of contract manufacturing, causing baby care volumes to drop by 12%. Feminine care sales volumes were 2% lower, which largely reflects the market trends. We benefited from the continuing growth of the adult care market, albeit with a modest 1% volume growth. Reason is that we have a large exposure to the more stable healthcare channel. To capture further growth in the retail channel, we're currently ramping up the capacity. Our sales prices were slightly lower, reflecting the carryover from the lower sales price in 2024, as well as some targeted price investments, and our product mix improved at the same time and more than compensated for this. Forex fluctuations had a small negative impact, mostly linked to the depreciation of the British pound, the Australian dollar, and especially the U.S. dollar. Let's move now to the adjusted EBITDA bridge on the next slide. On the EBITDA bridge, you can see the EUR 40 million impact of the lower revenue on adjusted EBITDA. It includes also lower absorption of fixed costs. Positive is that our cost transformation journey continues, and this year we generated EUR 69 million net savings, creating a 5% efficiency gain on our operating base. This encompasses efforts across the organization and includes the first benefits from the Belgian footprint transformation. We could have done more had volumes been higher. These continued efforts compensated most of the cost increases, but leaving an EUR 8 million negative net cost impact. Raw materials prices rose by about 4%, mainly driven by higher indices. The impact was across inputs, but especially in packaging, super absorbent polymers, and fluff. Raw material price indices spiked in H1, but came down since. But on average, they're still higher than in 2024. Other operating costs rose by about 8%. A large part is linked to inflation of salaries, logistics, and other services. Some were also caused by the supply chain inefficiencies we faced mainly in the first half of the year. Think, for example, to our outage at our Segovia plant. Despite all these challenges in 2025, we managed to keep an Adjusted EBITDA margin of 10%, which is 2 percentage points lower than last year. How this revenue and margin translates in net profit and also including the divested emerging markets, can be seen on the next slide. Adjusted EBITDA. Adjusted profits from continuing operations was EUR 34 million, as compared to EUR 76 million in 2024. The decline can be fully explained by the lower Adjusted EBITDA. In 2025, we had much lower restructuring costs as compared to 2024. These represented some EUR 19 million and were mostly non-cash because caused by impairments of obsolete assets and intangibles. Profits from continuing operations, which includes also the non-recurring costs, thereby amounted to EUR +60 million and is therefore more or less in line with 2024, which ended at EUR 21 million. As to the emerging markets, we posted EUR 190 million loss for Brazil and Turkey, and this loss is entirely caused by the non-cash accounting impact from currency translation reserves. These were accumulated over the many years in the past, and these are recycled through the P&L once the divestment is completed, and this costs EUR 210 million combined loss in 2025, but as I repeated already, it's non-cash. With the last divestments executed, only the core business is left. The result is much stronger- is a much stronger balance sheet with lower debt, which we will discuss later. Let's now move to the cash flow on the next slide. Here you'll find a bridge explaining how the Adjusted EBITDA of EUR 184 million translates free cash flow of EUR -25 million. Net working capital changes were largely neutral, with an increase in discontinued operations offset by an improvement in our core business. That latter core business improved from 5.4% to 5.1% over sales, mainly thanks to lower inventories, lower receivables, and higher factoring. We have a EUR 12 million negative impact from employee liability changes, as we accrued lower variable remuneration in the EBITDA of 2025, which will lead, of course, to lower cash payouts in 2026. CapEx was EUR 81 million, representing 4.5% of the revenue of our core business, and a non-recurring cash out amounted to EUR 30 million, mainly due to the already provisioned Belgian footprint restructuring. This free cash flow before financing to EUR +18 million. Cash out related to financing was EUR 43 million, higher than in 2024 due to the high-yield bond refinancing and a favorable interest rate swap, which came at maturity end of 2024. This free cash flow to equity holders to EUR -25 million, as I told you before. Then we go to the net debt. Our net debt reduced by 6% from EUR 612 million in 2024 to EUR 577 million in 2025. Apart free cash flow, which i explained on the previous slide, we finalized the divestments of the Brazilian and Turkish business, which brought EUR 131 million net proceeds. We, however, had to reclassify EUR 34 million of cash residing in Algeria, dating from the divestment in 2024, and it was reclassified as a financial asset. But currently, we're making good progress in repatriating this money. We also had an increase in lease liabilities and some other non-cash elements, which amounted EUR 27 million and relates to future commitments related to the renewal of some real estate leases. Next, we have the share buyback program, which was launched in 2024, whereby we acquired EUR 1.5 million shares to cover the future potential option plans, with an impact of EUR 11 million in 2025. This brings us, thus, year-on-year to the reduction of net debt by 6% and gross debt by 12%. Just to summarize, if we look at our gross debt, which is EUR 647 million, it's at the right side of the slide. You can see it consists of EUR 145 million of leases, of course, the EUR 400 million of high-yield bonds, and then we have the revolving credit facility, of which we have drawn EUR 100 million, which is a bit more than one-third of the total facility. Then before I pass the word back to Laurent, we can have a look at the leverage ratio. In this graph, you can see the evolution since the end of 2022. The net debt you can find in the middle in green, and that's reduced year-over-year. We're constantly deleveraging the net debt. The last 12 months, Adjusted EBITDA, which is at the top in blue, improved consistently year-over-year until the end of 2024. In 2025, we have the decline because of the challenging year, but also, of course, the scope reduction following the different divestments. In yellow, then at the bottom, you find the ratio of both representing the leverage ratio. It improved from 6.4x at the end of 2022 to 3.3 at the end of 2023, 2.5 at the end of 2024, and now we return back just above 3 at 3.3x at the end of 2025. Nevertheless, the balance sheet remains healthy. The leverage ratio remains below the 3.5x covenant, which is a threshold in the RCF. Important to stress is that we have ample liquidity, namely EUR 240 million, which is the cash of EUR 70 million and about 2/3 of the RCF, which is undrawn. The maturity of our debt is extended to at least 2029. Now, I'm very pleased to pass the word back to Laurent. Thanks, Geert. After two solid years in 2023 and 2024, 2025 was more difficult. So how do we see 2026? And I will start with the overall market conditions that we anticipate to remain pretty similar to 2025 overall, with low consumer confidence and continued promotional activity by A-brand. Yet, we equally expect the adult care momentum to continue and overall retail brand to remain a compelling consumer proposition with opportunity to grow share. On top of this general setting, the following elements are reflected in our assumptions. We expect birth rates in Europe to drive overall baby care demand slightly lower, as it did in 2025. In North America, worth mentioning that our contract manufacturing current sales level will create a negative comparison in the first half of 2026, and especially in the first quarter, whereas you might remember, we had anticipated shipments at the end of Q1 2025, ahead of the trade tariff threats between the U.S. and Mexico. And in the other smaller overseas business that we have, we continue to review our portfolio with targeted exits of unprofitable contracts. So let me now share how this will translate to our ambition for 2026. We target the Adjusted EBITDA to improve by 10% as we accelerate our extended cost transformation program throughout the year and progressively return to more stable operations. This EBITDA improvement will be gradual, starting from a soft first quarter, which is expected in line with the fourth quarter of 2025, but therefore lower than the strong first quarter that we had in 2025. This improvement is underpinned by overall largely stable revenue for the full year. Here again, you should expect a lower Q1 versus prior years for the reason that I just explained, and then volume grows to pick up in subsequent quarters. free cash flow after financing to be back in positive orders, driven by this higher Adjusted EBITDA, lower restructuring charges, and a continued effort to drive our working capital down. This, in turn, will lead leverage down to 3x or better by the end of the year. To deliver this plan, our priorities are clear, as presented in the next slide. First, resume volume growth. This includes ramping up the existing and newly secured contract, as well as the benefit of the additional capacity we've added in adult. Second, continue our productivity program with an extended cost transformation initiative, which includes an adjustment of our organization to our new scope of business. And third, a laser focus on improving cash conversion. In parallel, we started a strategic review with a clear focus on value creation. We want to go fast, whether by improving delivery and speed of our current plan, or by adding new elements to create incremental opportunities. And we will update you on a regular basis as progress is being made. This closes our prepared remarks. Geert and I are now ready to take your questions. Thank you, Laurent. Geert, for the Q&A session, if you wish to ask a question, please dial the pound key followed by five to enter the queue, and if you wish to withdraw your question, please dial the pound key followed by six. The first question is coming from Wim Hoste. Your line is open. Please go ahead. Yes, hello. Thank you for taking my questions. I have a couple of one. First one on the U.S. market. How should we think about revenue evolution in 2026? You explained the situation with the contract manufacturing drop in preceding quarters, but will this contract manufacturing further drop in 2026? How much support can you get from recently signed or started up contracts? Can you offer a little bit of clarity on that as well, please? So that's the first question. Second one is more general one, pricing versus raw material evolution. If you can elaborate on that as well. And then a third and smaller one is, how much CapEx budget have you included free cash flow guidance? that would also be helpful. Thank you. All right. Thank you, Wim, for your questions. I'll take on the first two questions, and then Geert will address the third one. So on the U.S. market growth, as you know, we don't provide guidance of expected growth by region, but the dynamic that was described is what you should continue to expect, which is we're continuing to grow on our retail brand business. And year-over-year, our contract manufacturing sales in 2026 will be lower than the full year 2025. Overall, with the two blocks, we expect the U.S. to contribute more growth than Europe in 2026. That's for your first question. On the second question on pricing versus raw material, we expect stable to slightly positive contribution of raw material in 2026 versus 2025. And at the same time, we expect that as we have some contract renew or tenders that we participate to, we might strategically invest on targeted customers to secure our gains. So, this is the dynamic that we always have, where we try to remain competitive as we see raw material cost evolution. And on CapEx, I will pass it on to you. Hello, Wim. On CapEx, yeah, we keep in fact to the guidance we gave several times, that at the end of 2025, we wanted to go back to a level of 3.5%-4.5% of CapEx to revenue. So that's what we're heading for, for, and which is sufficient to execute our plans. Okay. Very clear. Thank you. Thank you, Wim. The next question comes from Karine Elias from Barclays. Karina, your line should be open. Hi, thank you again for the presentation, and thanks for taking my questions. Just going back to your, the guidance on the full year EBITDA. Obviously, Q1 has been a tough comp, so I understand that the decline that you mentioned, which would be similar to Q4. But just as we think through the year, what's your visibility like into Q2? Should we expect the EBITDA improvement to start showing from Q2 onwards? Because on my numbers, if you know, if we've got a EUR 15 million decline in Q1, that means a EUR 37 million improvements in Q2, Q3 to Q4 to get your guidance. Just wondering a little bit how we should think about the cadence of the EBITDA. Thank you. Yeah. Thanks, Karine, for your question. So the way we look at it, and then you phrased it well also, we expect Q1 in line with the last quarter of last year of 2025. Then indeed, as we said in our guidance, we expect gradual improvements throughout the year. What are the drivers? Of course, there are different elements. First of all, it's the continuous productivity improvement, which we're constantly working on with the cost transformation program, which we also had last year. But this year, we project a much more stable year, because there was quite some instability coming from external factors that happened, but also the changes we did in our organization. So we have the Belgium footprint reorganization that we were executing. That's ending at the end of Q1, so that's finalized, so that will bring a lot more stability. And also in North America, we had an important ramp-up as well in production, as in sales. And also there, we see much more stability, which will help us to drive that EBITDA growth. Great. But just to clarify, so we would expect to start seeing that from Q2 onwards, or is it gonna be more back-ended? From Q2. So it's really throughout, it's step by step, quarter by quarter. Understood. That's very clear. Thank you. All right. Thank you, Karine. The next question comes from Usama Tariq, from ABN AMRO - ODDO BHF. Usama? Hi, good afternoon. Thank you for the opportunity. I just have one set of questions. Could you provide some view on the non-recurring cash outflow for next year? So this year was around EUR 30 million. So any guidance there or point there would be very helpful. And just my second question would be, it's a bit more general, but please correct me if I'm wrong, Ontex still has some exposure to Russian assets. Would that also be considered into the strategic review going forward, or if you could provide any pointers there, that would be very grateful. Thank you so very much. Hello, Usama. I take your first question on the non-recurring. There, as a management, we, we've always had the intention to decrease our non-recurring, so we also keep to that intention. That means that, based on the plans we have at this moment, we still have about EUR 10 million of the last phase of the footprint in Belgium. So that's the big provision we made in 2024, and what we gradually executed over the one year and half, more or less. So there's EUR 10 million, but it's already in the P&L, so it's a cash out. And, based on the current plans we have and the further transformation, we foresee more or less another EUR 10 million. All right, then, Usama. Laurent, I will tackle your second question. Yes, we still have our assets in Russia. You know, our Russian business is about 5% of our total revenues. The strategic review is actually a pretty broad exercise where we review where we compete in different categories, different markets, and where we should allocate our resources to maximize value creation. And as part of this, if it's relevant to review our position with this market, we will, but it's way too early to preclude any conclusion. Okay. Thank you for the opportunity. Thank you. Thank you. Thank you, Usama. Just as a reminder, if you wish to ask a question, please dial the pound key followed by six. If you wish to take it back, pound key, followed by five and followed by six to take it back. The next question comes from Fernand De Boer from Degroof Petercam. Fernand, your line should be open. Yes, good morning. Actually, I have one question. So you're guiding for a lower EBITDA in Q1, first year, last year, so that means that on a 12-month basis, your EBITDA also comes down. What is your cash flow outflow expected for Q1 or first half? Because I think then you still are within the covenants, but if you look at that, then you could be very close. And what happens if you would go above the 3.5 x? Okay, Fernand, I will answer on that question. Yeah, we're not giving guidance by quarter, that you know, on cash flow, but of course, we are very aware on the quarter to quarter. We have, as Laurent said, a very clear cash focus. So that will be, it's something not we look at on a quarterly basis. It's on a weekly basis that we're on top of that. As to governance, you know, that we guide through to the towards the end of the year to go below three. That will not be in the first half of the year, but the purpose is to go down. It's also, for us, a covenant testing, I want to stress that one. It's always coming at the end half of half year, so we feel confident that we are, yeah, we're doing well, and we are within the target set. Okay. Maybe I missed it, but did you give an amount for factoring? Yeah, it's in the press release, but I can, I can tell you, of course, it's... Yeah, sorry. EUR 185 million. Yeah. I had to- No, no, sorry. --this day. You just received it. It's normal. Okay. You couldn't read everything. Thank you. That's perfect, normal. No, no, no. Thank you. Thank you, Fernand. Thank you. The next question comes from Rebecca Clements from JP Morgan. Rebecca, your line should be open. Good morning. Can you hear me? Yeah, we hear you well. Okay. Okay, great. Just following up on the accounts receivable factoring. You said it was EUR 185 million used at year-end. Is that correct? Yeah, that's right. Okay. I think you had said last year that you expected some working capital pressure because of reduced receivables. It and I think it was related to the securitization facility. Could you just talk us through, is that still the case, or do you expect there to be some negative impact on the receivable side through at least part of 2026 due to the lower sales? That's my first question. Yeah. Good, good question, Rebecca, but of course, working capital, we look to the total. So it's for us, inventory, accounts payable, accounts receivable. Factoring at year-end, it was a bit higher than normal because there was quite some invoicing just at the end of the year, so it's a bit accidental. That's also yeah, one of the reasons free cash flow was somewhat better than the guidance. But for the rest of our accounts payable, yeah, you have seen we don't give guidance on revenue, but we expect it to stabilize, and that means that our accounts receivable will be following the same pattern, and with a close follow-up, of course, on our DSO. Does it answer your question? Okay. Sort of. I was just wondering, because of, I guess, reduced- Given you know who you're selling to and which receivables go into that facility, I just wasn't sure if there would be some sort of temporary, potentially negative impact of not being able to submit receivables to that facility- No. that could impact you mid-year. Not really. No, it's, no... It's a normal operation. Okay. Okay, and then my second question is related to your visibility. So you said things are more stable now. I know last year, one of, one of the challenges in the second half was that circumstances changed more quickly than you could react to, and you ended up having some cost absorption issues from a manufacturing perspective. What gives you comfort that you feel the, the situation is more stable, whether it's North America baby care or European baby care? What, what gives you that, that sort of confidence in it being more stable? Because it seemed last year that it was quite difficult for, for you guys to predict kind of where volumes were going, and plan accordingly. Yeah, Rebecca, thanks for the question. It's Laurent. I think when we talked about stability here, we were referring to our operations, not necessarily the sales pattern. We fundamentally, what we're doing to be better prepared, because we expect that there will still be some volatility from time to time in our sales, is to improve forecast accuracy and our ability to anticipate with leading indicators that would allow us to adjust our operation and our production ahead of time. And as at the same time, we're gonna have less movements of, you know, startup of new lines, relocation of lines from one factory to the other, et cetera, it will be in the context of a more stable operational framework, which will help us to be much more fluid and to create less inefficiency when you have some volatility in the demand pattern. Okay. That's helpful. Okay. Can I get one more question in or no? Go ahead. Is, yeah, is that okay? Yes, go ahead. Yeah, sorry, Rebecca. Do you, was most of the issues around not being able to react as quickly enough, was that North American baby care, or was that across baby care globally for you? It was across Baby Care on both sides. You know, proportionately, obviously, it was a bigger impact on the U.S., but Europe also, we observe a change in behavior in the market. And, you know, our role is to partner with our customers to help them adapt to that situation. So we saw a much greater promotional activity from a brand in Europe, and we're talking to our key partners to share our analysis with them and come up with ideas and proposition for them, how best to be competitive in this new market reality, to protect their position and for them to win on the marketplace. So on both sides. Okay. Okay, thank you. That's very helpful. Yeah. Thank you, Rebecca. The next question comes from Charles Eden, from UBS. Charles, we're listening. Hi, thank you very much for taking my questions. Two for me, please. Just, just firstly, on the EBITDA bridge, that 10% growth, which is, what? EUR 17 million-EUR 18 million year-on-year. I hear you, flat revenue, so I guess no real drop-through from the top line. SG&A and other inputs, broadly stable, maybe EUR 1 million-EUR 2 million contribution. Is there anything else in the bridge, or are you basically saying EUR 15 million of cost savings year-on-year gives you the growth? And maybe if that is true, where exactly are the cost savings coming from? Is it headcount reduction? Is it efficiencies? Is it combination? Any color you could give us there would be appreciated. And then my second question is just on the strategic review, and, Laurent, firstly, welcome. But secondly, just in terms of expectations on the strategic review, obviously the business has changed a lot, over the last few years. What can we expect you to be focusing on during this strategic review? I assume there's not change of portfolio top of list, but, but what are the areas that are on top of that list for that strategic review? Thank you. Sure. I'll address quickly your first question on the EBITDA. I think that you're right, that our continued productivity will be the key driver of our margin expansion and therefore EBITDA growth. And the second element that you need to keep in mind is mix. We benefit from a favorable mix. So even within stable sales environment, the mix will be a positive contributor. On the building block of this cost productivity, they are the usual suspects in terms of, you know, we work with procurement on improving the mix of our suppliers, we work on manufacturing, on the efficiency of our lines, we're doing some re-networking analysis on logistics. We have the design to value initiative where we always cost optimize our product, and we're extending that in 2026 to also include some adjustment on our organization design to generate additional savings. So those would be the key building blocks. On the strategy review question, it is a pretty broad effort, as you could have read in our press release in January, where we basically are stepping back and are looking at where best to allocate resources, capital, to create maximum value for our shareholders, where we have the best chances to win and where it's growth. We believe that all our categories have potential. We have already done a huge focus effort to focus on Europe and North America. There is, you know, both have potential. Yes, what we're looking at is the new conditions to compete and how do we tweak, if you want, the formula between, the focus on, on different categories, what it takes to compete, and therefore, what is the proper footprint and organization to maximize our cost in order to be able to continue to, grow volume in those categories. So a bit long, long answer to your questions, because this is exactly the goal of that effort, and our commitment is that as we progress, we will share, our conclusions in our subsequent, earnings calls, with you. Understood. Thank you. Thank you, Charles. The next question comes from Maxime Stranart from ING. Maxime, your line should be open. Hi. Good morning, hope you can hear me well. Two questions from my side, if I may. Apologies if it has been asked already, a bit of delay here. First of all, looking at your EBITDA guidance and the cadence throughout the year, can you elaborate on when do you see the inflection point coming in? Based on your guidance, I understand that EBITDA should decline by basically almost 20% in Q1. So just a view on how we should see the work panning out. Second question would be on restructuring. I think you announced previously that you wanted to accelerate savings and productivity improvement there. I think you mentioned EUR 40 million, of which some were to be included in SG&A and some in restructuring. Any of you can, you can share on that? That would be helpful. Thank you. Yeah. So, Maxime, your first question, our EBITDA guidance is that our Q1 is in line with last quarter of 25, and then we see a gradual improvement quarter by quarter. Is that answering your question? Yes, it does. Just want to cross-check there. So basically, if I look at last year, Q1 was good, Q2 was bad, Q3 was good. So just want to make sure I understand the phasing of your guidance correctly. Yeah. But indeed, last year was at a quite volatile pattern. That's not what we expect. And yeah, as you have seen, we give guidance on EBITDA, so we're of course also focused on revenue, but for us the productivity improvements are important. The mix improvements, the stability that we built in the business, and that's what will drive that continuous growth throughout the quarters. That's very clear. Thank you. Yeah. The second question was on restructuring. Maybe here you can add on that as well in terms of- Yeah. What to expect. Yeah. So restructuring, yeah, linking to what Laurent said before, for us, we have existing plans, which is on one end, the continuation of the plans in the past, but all with new initiatives, because we're talking about add-on savings. And yeah, in the strategic review, they will look at what extra things they can untap as potential. But in the restructuring plan, which is part of the guidance we give, they yeah, there's a whole bucket of savings with the restructuring costs that I mentioned before, of still above what we still have to pay on building out. On building out the Belgian footprint, we still have EUR 10 million of restructuring costs, and there's another EUR 10 million we expect this year to execute the existing plans. Okay, got it. Apologies as I missed the beginning of the call. Just want to clarify, then you basically expect a EUR 20 million, basically, cash outflow from restructuring. Just want to make sure. Yeah, that's right. That's- That's right. Based on the existing plans. Okay, perfect. Thank you for your answers. Thank you, Maxime. There are no more questions, so I hand it back over to you, Laurent, for your closing remarks. Right. Thank you, Geoff. 2025 was a year that did not live up to our expectations. Yet we continued to deliver on our transformation program, and we showed some solid resilience, including in our profitability and in our ability to compete in the marketplace. We remain upbeat on the potential we have in the different markets in which we participate. The strategic review is a needed step to sharpen our trajectory and focus even more on where we can create compelling value, and we will share our conclusions and the year progresses. We have very clear priorities set to deliver our 2026 plan. With a laser focus on financial discipline and cash, we are confident we can start to rebound, even if the first part of the year will continue to be subdued. The priorities we shared today are the ones of our close to 5,000 employees, who give their best every day, so we deliver a great proposition to our customers. They understand the need for us to rebuild trust and to adjust our journey to best reflect the market realities. With that, thank you for joining, and have a great day. This concludes the call. Bye-bye. Bye-bye.